IN2012DN03297A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03297A IN2012DN03297A IN3297DEN2012A IN2012DN03297A IN 2012DN03297 A IN2012DN03297 A IN 2012DN03297A IN 3297DEN2012 A IN3297DEN2012 A IN 3297DEN2012A IN 2012DN03297 A IN2012DN03297 A IN 2012DN03297A
- Authority
- IN
- India
- Prior art keywords
- disorders
- solvates
- treatment
- salts
- pharmaceutical compositions
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 3
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 2
- 206010021518 Impaired gastric emptying Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000001288 gastroparesis Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000017701 Endocrine disease Diseases 0.000 abstract 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract 1
- 206010054048 Postoperative ileus Diseases 0.000 abstract 1
- 206010049416 Short-bowel syndrome Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 201000007637 bowel dysfunction Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 abstract 1
- 150000001923 cyclic compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000016361 genetic disease Diseases 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D269/00—Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups C07D261/00 - C07D267/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24736209P | 2009-09-30 | 2009-09-30 | |
| PCT/US2010/050661 WO2011041369A1 (fr) | 2009-09-30 | 2010-09-29 | Sels, solvates et compositions pharmaceutiques d'agonistes macrocycliques du récepteur de la ghréline et leurs procédés d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03297A true IN2012DN03297A (fr) | 2015-10-23 |
Family
ID=43826618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3297DEN2012 IN2012DN03297A (fr) | 2009-09-30 | 2010-09-29 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110245159A1 (fr) |
| EP (1) | EP2482813A4 (fr) |
| JP (1) | JP2013506676A (fr) |
| KR (1) | KR20120081166A (fr) |
| CN (1) | CN102781441A (fr) |
| AU (1) | AU2010300689A1 (fr) |
| BR (1) | BR112012007183A2 (fr) |
| CA (1) | CA2775925A1 (fr) |
| EA (1) | EA201270497A1 (fr) |
| IL (1) | IL218938A0 (fr) |
| IN (1) | IN2012DN03297A (fr) |
| MX (1) | MX2012003912A (fr) |
| WO (1) | WO2011041369A1 (fr) |
| ZA (1) | ZA201202307B (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7491695B2 (en) * | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
| US20090198050A1 (en) * | 2003-06-18 | 2009-08-06 | Tranzyme Pharma Inc. | Macrocyclic Modulators of the Ghrelin Receptor |
| US8921521B2 (en) | 2003-06-18 | 2014-12-30 | Ocera Therapeutics, Inc. | Macrocyclic modulators of the Ghrelin receptor |
| US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| CA2528375C (fr) | 2003-06-18 | 2013-11-19 | Tranzyme Pharma, Inc. | Antagonistes macrocycliques du recepteur de motiline |
| EP3159352B1 (fr) | 2007-03-28 | 2023-08-02 | President and Fellows of Harvard College | Polypeptides piqués |
| KR102104762B1 (ko) | 2010-08-13 | 2020-04-24 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| CA2864120A1 (fr) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Macrocycles peptidomimetiques reticules par triazole et par thioether |
| NZ627528A (en) | 2012-02-15 | 2016-05-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
| BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
| KR20170058424A (ko) | 2014-09-24 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 용도 |
| WO2016077498A1 (fr) | 2014-11-12 | 2016-05-19 | Lyric Pharmaceuticals Inc. | Traitement de l'intolérance à l'alimentation entérale |
| SG11201707750YA (en) | 2015-03-20 | 2017-10-30 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| EP3551047A1 (fr) * | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7491695B2 (en) * | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
| US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| KR20070009574A (ko) * | 2004-02-17 | 2007-01-18 | 토마스 이. 존슨 | 매크로사이클릭 화합물의 형성을 위한 방법, 조성물 및장치 |
| JP5383037B2 (ja) * | 2004-02-27 | 2014-01-08 | リブ−エックス ファーマシューティカルズ，インコーポレイテッド | 大環状化合物およびそれらを製造し使用する方法 |
| US8088733B2 (en) * | 2006-07-06 | 2012-01-03 | Tranzyme Pharma Inc. | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders |
-
2010
- 2010-09-29 EA EA201270497A patent/EA201270497A1/ru unknown
- 2010-09-29 WO PCT/US2010/050661 patent/WO2011041369A1/fr not_active Ceased
- 2010-09-29 JP JP2012532258A patent/JP2013506676A/ja not_active Withdrawn
- 2010-09-29 AU AU2010300689A patent/AU2010300689A1/en not_active Abandoned
- 2010-09-29 CA CA2775925A patent/CA2775925A1/fr not_active Abandoned
- 2010-09-29 IN IN3297DEN2012 patent/IN2012DN03297A/en unknown
- 2010-09-29 MX MX2012003912A patent/MX2012003912A/es not_active Application Discontinuation
- 2010-09-29 US US12/937,040 patent/US20110245159A1/en not_active Abandoned
- 2010-09-29 BR BR112012007183A patent/BR112012007183A2/pt not_active IP Right Cessation
- 2010-09-29 CN CN2010800547916A patent/CN102781441A/zh active Pending
- 2010-09-29 EP EP10821147A patent/EP2482813A4/fr not_active Withdrawn
- 2010-09-29 KR KR1020127010634A patent/KR20120081166A/ko not_active Withdrawn
-
2012
- 2012-03-29 IL IL218938A patent/IL218938A0/en unknown
- 2012-03-29 ZA ZA2012/02307A patent/ZA201202307B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013506676A (ja) | 2013-02-28 |
| KR20120081166A (ko) | 2012-07-18 |
| EP2482813A4 (fr) | 2013-02-27 |
| CA2775925A1 (fr) | 2011-04-07 |
| CN102781441A (zh) | 2012-11-14 |
| BR112012007183A2 (pt) | 2017-06-20 |
| ZA201202307B (en) | 2012-12-27 |
| US20110245159A1 (en) | 2011-10-06 |
| IL218938A0 (en) | 2012-07-31 |
| EP2482813A1 (fr) | 2012-08-08 |
| WO2011041369A1 (fr) | 2011-04-07 |
| EA201270497A1 (ru) | 2012-10-30 |
| MX2012003912A (es) | 2012-08-17 |
| AU2010300689A1 (en) | 2012-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN03297A (fr) | ||
| MA29432B1 (fr) | Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques | |
| ATE502939T1 (de) | Disubstituierte alkyl-8-azabicycloä3.2.1üoktan- verbindungen als mu-opioid-rezeptorantagonisten | |
| MX2010002171A (es) | Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu. | |
| TW200800981A (en) | 8-azabicyclo[3.2.1]octane compounds as MU opioid receptor antagonists | |
| WO2008021851A3 (fr) | Nouveaux composés comme antagonistes ou agonistes inverses pour les récepteurs d'opioïdes | |
| WO2007106181A3 (fr) | Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques | |
| NO20070213L (no) | Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser | |
| UA92670C2 (ru) | Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе | |
| WO2008021849A3 (fr) | Nouveaux composés comme antagonistes ou agonistes inverses à des récepteurs d'opioïdes | |
| PL1957484T3 (pl) | Antagoniści receptora glukagonu, wytwarzanie i zastosowanie w lecznictwie | |
| EA201270039A1 (ru) | Новые агонисты gpr 119 | |
| MX2010010339A (es) | Ciclohexildiaminas sustituidas. | |
| ATE542795T1 (de) | Benzylpiperazinderivate als motilin- rezeptorantagonisten | |
| WO2009076408A3 (fr) | Dérivés de 3-carboxypropyl-aminotétraline et composés associés en tant qu'antagonistes du récepteurs mu-opioïde | |
| MX2013006768A (es) | Moduladores de receptor de glucagon. | |
| MX2012000685A (es) | Compuesto de 3-fenoximetilpirrolidina. | |
| WO2009076399A3 (fr) | Composés d'aminotétraline en tant qu'agonistes de récepteur opioïde mu | |
| DK1951659T3 (da) | Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf | |
| GB0524814D0 (en) | Compounds | |
| IL195969A0 (en) | Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition | |
| ZA200705524B (en) | Synthesis of CCR5 receptor antagonists | |
| MY179041A (en) | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | |
| MX2011013149A (es) | Acido (s)-2-bencil-3-((3r,4r)-4 - (3 - carbamoilfenil) -3,4-dimetilpiperidinil) propanoico y sales delmismo como antagonistas de receptores opioides. | |
| UA97374C2 (ru) | Производные азаиндола с комбинацией частичного агонизма к никотиновому ацетилхолиновому рецептору и ингибирование обратного захвата допамина |